Clinical trials: Oral Anticoagulant
Atrial Fibrillation, Stroke
DOAC in Chinese Patients With Atrial Fibrillation
Direct oral anticoagulants (DOACs) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF).
- Conditions
- Atrial Fibrillation, Stroke, Stroke, Acute, Brain Diseases
- Trial name
- DOAC-REAL (NCT05378035)
- Testing
- Blood Tests
- Where
- Hong Kong
- Volunteers
- 427 people
- Sponsor
- Chinese University of Hong Kong
Prevention, Venous Thromboembolism
A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.
- Trial name
- NCT01181167
- Testing
- edoxaban, enoxaparin sodium
- Where
- 2 sites in Japan
- Volunteers
- 610 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Ischemic Stroke, Anticoagulant Adverse Reaction
Evaluataion of NOAC Levels in Acute Stroke
Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended over warfarin in preventing stroke and thromboembolism among patients with atrial fibrillation (AF) in several guidelines.
- Trial name
- NCT06144866
- Testing
- Dabigatran, rivaroxaban, apixaban, edoxaban
- Where
- Taiwan
- Volunteers
- 1,000 people
- Sponsor
- National Taiwan University Hospital
Non-Valvular Atrial Fibrillation
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
The primary objectives of this study are to compare the risk of major bleeding and stroke/systemic embolism (SE) events among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating OAC warfarin…
- Trial name
- ARISTOPHANES (NCT03087487)
- Where
- United States
- Volunteers
- 466,991 people
- Sponsor
- Bristol-Myers Squibb
Direct Oral Anticoagulants (DOACs), Femoral Fractures
Impact of Treatment With Oral Anticoagulants of Patients With Fractures of the Upper End of the Femur
In 2023, oral anticoagulant treatments (anti Xa: apixaban , rivaroxaban, etc.) are tending to replace anti vitamin K treatments in many medical indications. Their prescription is increasing rapidly in the elderly.
- Conditions
- Direct Oral Anticoagulants (DOACs), Femoral Fractures, Surgery
- Trial name
- ANTI_XA AOD (NCT06382584)
- Testing
- Femoral fracture surgery
- Where
- France
- Volunteers
- 610 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Acute Pulmonary Embolism
Tinzaparin in the Treatment of the Acute Pulmonary Embolism
The purpose of this study is to evaluate the feasibility of the long-term treatment of pulmonary embolism with tinzaparin compared to oral anticoagulants.
- Trial name
- NCT00711308
- Testing
- tinzaparin, acenocoumarol
- Where
- 4 sites in Spain
- Volunteers
- 102 people
- Sponsor
- Complejo Hospitalario Xeral-Calde
Stroke
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified.
- Trial name
- NAVIGATE ESUS (NCT02313909)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036)
- Where
- 454 sites in United States, Argentina and 29 more
- Volunteers
- 7,213 people
- Sponsor
- Bayer
Cryptogenic Ischemic Stroke, Patent Foramen Ovale
PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years
To assess whether PFO closure plus antiplatelet therapy is superior to antiplatelet therapy alone and whether oral anticoagulant therapy is superior to antiplatelet therapy to prevent stroke recurrence in patients aged 60 to 80…
- Trial name
- CLOSE-2 (NCT05387954)
- Testing
- Transcatheter PFO closure, Oral Anticoagulant, Direct-Acting, Antiplatelet therapy
- Where
- 42 sites in France
- Volunteers
- 792 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
The goal of this observational study is to learn the safety and efficacy of edoxaban and rivaroxaban in Chinese population with the age range from 18 to 80 years who take edoxaban or rivaroxaban to treat their cerebral venous…
- Conditions
- Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders, Anticoagulation Treatment, Anticoagulant Therapy
- Trial name
- NCT06947707
- Where
- China
- Volunteers
- 1,486 people
- Sponsor
- Xuanwu Hospital, Beijing
Cerebrosinovenous Thrombosis
Efficacy and Safety of Oral Rivaroxaban in Cerebrosinovenous Thrombosis
The study seeks to fill the gaps regarding safety and efficacy of rivaroxaban and standard anticoagulant. therefore the current study was planned with the aim to determine the safety and efficacy of rivaroxaban and standard…
- Trial name
- NCT07523347
- Testing
- Rivaroxaban, Warfarin
- Where
- Pakistan
- Volunteers
- 75 people
- Sponsor
- Muhammad Aamir Latif
Hemostasis
Study of Hemostasis During the Atrial Fibrillation Ablation Procedure
Anticoagulation monitoring is done by monitoring the ACT (Activated Clotting Time) with an objective greater than 300 s. Until now, treatment with direct oral anticoagulant (for the prevention of thromboembolic events of atrial…
- Trial name
- EHPAFAVE (NCT05128110)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Strasbourg, France
Atrial Fibrillation (AF), Ischemic Stroke
Risk Score of Embolism in Patients With AF Undergoing DOAC Therapy
Acute ischaemic strokes occur despite the use of direct oral anticoagulants (DOACs). Evidence-based scale is necessary to assess ischemic stroke risk in atrial fibrillation (AF) patients.
- Trial name
- SAFER-DOAC (NCT07713537)
- Testing
- DOAC Level
- Where
- 2 sites in Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Atrial Fibrillation, Stroke
AI-Assisted Workflow for Occult Atrial Fibrillation Detection After Ischemic Stroke: A Prospective Randomized Trial
We hypothesize that an AI-guided AF risk stratification approach, particularly when combined with intensified rhythm monitoring using wearable devices and extended ECG patches, will significantly increase AF detection rates…
- Conditions
- Atrial Fibrillation, Stroke, Artificial Intelligence
- Trial name
- AI-AFIS (NCT07540065)
- Testing
- Active Follow-up Group, Standard Follow-up Group
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- National Taiwan University Hospital
Atrial Fibrillation, Periodontal Disease
Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants
The purpose of this study is to evaluate the safety of a protocol which does not suspend the new oral anticoagulants (dabigatran, rivaroxaban and apixaban) in front of dental extractions in patients with non-valvular atrial…
- Conditions
- Atrial Fibrillation, Periodontal Disease, Hemorrhage
- Trial name
- NCT03181386
- Testing
- Rivaroxaban, Dabigatran and Apixaban, Warfarin
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo General Hospital
Stroke
Urin-based Point-of-Care Testing for Direct Oral Anticoagulants in Stroke Patients
The goal of this study is to test a urine-based point-of-care testing device for direct oral anticoagulants in patients with stroke.
- Trial name
- UPTURN (NCT06037200)
- Testing
- Urin-based test by the DOASENSE Dipstick Device
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- University of Giessen
Embolism and Thrombosis, Hemorrhage
Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants
The purpose of this study is to investigate the preventability of serious adverse drug reactions (ADRs) related to the use of direct oral anticoagulants (DOACs).
- Trial name
- ADR-OAC (NCT02720328)
- Testing
- Blood samples for DOAC measurement
- Where
- 2 sites in Belgium
- Volunteers
- 102 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Acute Myocardial Infarction, Unstable Angina
PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy
Approximately 5 to 8% of patients undergoing percutaneous coronary interventions requires chronic anticoagulant therapy due to atrial fibrillation or other clinical entities.
- Conditions
- Acute Myocardial Infarction, Unstable Angina, Chronic Stable Angina
- Trial name
- PERSEO (NCT03392948)
- Where
- 10 sites in Italy
- Volunteers
- 1,080 people
- Sponsor
- Italian Society of Invasive Cardiology